Literature DB >> 8820116

Method to measure apolipoprotein B-48 and B-100 secretion rates in an individual mouse: evidence for a very rapid turnover of VLDL and preferential removal of B-48- relative to B-100-containing lipoproteins.

X Li1, F Catalina, S M Grundy, S Patel.   

Abstract

We have developed a procedure to measure the rates of apolipoprotein (apoB) and triglyceride secretion from the liver of an individual mouse. Using the well-characterized method of Triton WR-1339 injection to block peripheral removal of newly secreted VLDL, the rate of triglyceride accumulation is monitored and at the end of the experimental period, blood is extracted for quantitative VLDL preparation. ApoB species in isolated VLDL are analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and the mass of the apoB-48 and apoB-100 species are estimated by Coomassie staining and laser densitometric scanning, using known quantities of LDL-apoB-100 as standards. This methodology was applied to measure the rate of apoB secretion in male and female FVB/N mice and we found that the molar ratio of newly secreted ApoB-48 to B-100 is 4.6 in the male, and 3.8 in the female. Measurements of the steady state apoB levels indicate that liver-derived apoB-48 is cleared from the circulation 7.1 times faster than B-100 in the male and 4.7 times faster in the female mouse. VLDL apoB-48 fractional turnover is approximately 1800 pools per day in both the male and female mouse (1814 +/- 139 vs. 1831 +/- 365 respectively, P = 0.92). ApoB-100 fractional turnover rates are much slower and show a statistically significant difference between males and females (255 +/- 19 pools per day vs. 386 +/- 65 pools per day, respectively, P = 0.006). This procedure provides for quantification of secretory rates of these apo proteins in vivo, and may be useful for studying the effects of genetic manipulation on the simultaneous secretion of apoB-48- and apoB-100-containing VLDL, afforded by the panoply of transgenic mouse models now available for study, as well as for effects of diet and drug therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8820116

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  25 in total

1.  Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice.

Authors:  Kebin Zhang; Ling Li; Yajuan Qi; Xiaoping Zhu; Boyi Gan; Ronald A DePinho; Travis Averitt; Shaodong Guo
Journal:  Endocrinology       Date:  2011-12-06       Impact factor: 4.736

2.  Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.

Authors:  Silvia Bijland; Elsbet J Pieterman; Annemarie C E Maas; José W A van der Hoorn; Marjan J van Erk; Jan B van Klinken; Louis M Havekes; Ko Willems van Dijk; Hans M G Princen; Patrick C N Rensen
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

3.  Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB.

Authors:  R A Srivastava; L Toth; N Srivastava; M E Hinsdale; N Maeda; A B Cefalu; M Averna; G Schonfeld
Journal:  Mol Cell Biochem       Date:  1999-12       Impact factor: 3.396

4.  CETP does not affect triglyceride production or clearance in APOE*3-Leiden mice.

Authors:  Silvia Bijland; Sjoerd A A van den Berg; Peter J Voshol; Anita M van den Hoek; Hans M G Princen; Louis M Havekes; Patrick C N Rensen; Ko Willems van Dijk
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

5.  Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition.

Authors:  Linda E Hammond; Patricia A Gallagher; Shuli Wang; Sylvia Hiller; Kimberly D Kluckman; Eugenia L Posey-Marcos; Nobuyo Maeda; Rosalind A Coleman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

6.  Sialidase down-regulation reduces non-HDL cholesterol, inhibits leukocyte transmigration, and attenuates atherosclerosis in ApoE knockout mice.

Authors:  Elizabeth J White; Gabriel Gyulay; Šárka Lhoták; Magdalena M Szewczyk; Taryne Chong; Mark T Fuller; Omid Dadoo; Alison E Fox-Robichaud; Richard C Austin; Bernardo L Trigatti; Suleiman A Igdoura
Journal:  J Biol Chem       Date:  2018-08-10       Impact factor: 5.157

7.  A novel NanoBiT-based assay monitors the interaction between lipoprotein lipase and GPIHBP1 in real time.

Authors:  Shwetha K Shetty; Rosemary L Walzem; Brandon S J Davies
Journal:  J Lipid Res       Date:  2020-02-06       Impact factor: 5.922

8.  GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization.

Authors:  Ko Kotani; Odile D Peroni; Yasuhiko Minokoshi; Olivier Boss; Barbara B Kahn
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  The serine hydrolase ABHD6 Is a critical regulator of the metabolic syndrome.

Authors:  Gwynneth Thomas; Jenna L Betters; Caleb C Lord; Amanda L Brown; Stephanie Marshall; Daniel Ferguson; Janet Sawyer; Matthew A Davis; John T Melchior; Lawrence C Blume; Allyn C Howlett; Pavlina T Ivanova; Stephen B Milne; David S Myers; Irina Mrak; Vera Leber; Christoph Heier; Ulrike Taschler; Jacqueline L Blankman; Benjamin F Cravatt; Richard G Lee; Rosanne M Crooke; Mark J Graham; Robert Zimmermann; H Alex Brown; J Mark Brown
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

10.  Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits.

Authors:  Haizhao Yan; Manabu Niimi; Fumikazu Matsuhisa; Huanjin Zhou; Shuji Kitajima; Yajie Chen; Chuan Wang; Xiawen Yang; Jian Yao; Dongshan Yang; Jifeng Zhang; Masami Murakami; Katsuyuki Nakajima; Yao Wang; Enqi Liu; Jingyan Liang; Y Eugene Chen; Jianglin Fan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-08-06       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.